Navigation Links
Certain Bone Drugs May Lower Breast Cancer Risk
Date:3/5/2010

Benefit from Fosamax, Boniva, Zometa does not apply to obese women, however

FRIDAY, March 5 (HealthDay News) -- Some types of bone-building drugs used to prevent and treat osteoporosis might reduce the risk of breast cancer, according to new research.

The study, which included 6,000 Wisconsin women aged 20 to 69, found that those who took bisphosphonate drugs such as Fosamax, Boniva and Zometa for more than two years were 40 percent less likely to develop breast cancer than were women who did not take the drugs.

However, the protective effective was seen only among women who were not obese.

"Obese women may have elevated estrogen levels, so underlying hormones may influence the ability of bisphosphonates to reduce breast cancer risk," the study's lead author, Polly Newcomb, head of the cancer prevention program at Fred Hutchinson Cancer Research Center in Seattle, said in a news release from the center.

The study is published online and in the March print issue of the British Journal of Cancer.

Just how bisphosphonate drugs affect the risk for breast cancer is unclear, but there are a number of possibilities.

"These drugs may affect cell function and be important in cell growth and death -- specifically the death of tumors or even premalignant disease," Newcomb said.

Also, previous studies have found that some kinds of bisphosphonates trigger tumor cell death, prevent tumors from establishing a blood supply and prevent cancer cells from binding to each other.

More information

The U.S. National Cancer Institute has more about breast cancer prevention.



-- Robert Preidt



SOURCE: Fred Hutchinson Cancer Research Center, news release, March 2, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Use of certain lipid measures not more effective in predicting coronary heart disease
2. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
3. MU researchers studying model to learn why certain cancers become resistant to drugs
4. New All-Natural Dietary Supplement Made from Muscadine Grape Skins Helps Inhibit Growth of Certain Cancers
5. Effectiveness of most PTSD therapies is uncertain
6. Value of Most Post-Traumatic Stress Treatments Uncertain
7. Certain Seizure Patients Need Emergency CT Scan
8. Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories
9. Certain Cholesterol Drugs Show Their Limits
10. ADHD Delays Growth of Certain Brain Areas
11. Stress hormone may hasten the progression of certain blood cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2019)... ... December 06, 2019 , ... Allegheny Health Network (AHN) has named ... joined AHN from WVU Medicine in May 2018, previously served as AHN’s Vice Chair ... interim chair since October and is also part of the pathology faculty at Drexel ...
(Date:12/6/2019)... ... December 06, 2019 , ... Dr. Scott Howell, a 2019 graduate of Trident ... the health benefits of coconut oil in the 7 November 2019 edition of ... Cardiometabolic Profile: A Structured Literature Review,” led by Dr. Hector O. Santos, examines the ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... ranging from launching exceptional products that help people embrace, achieve, and maintain a ... “We’ve never been more committed to our mission of impacting world health, so ...
(Date:12/4/2019)... ... December 04, 2019 , ... Healthcare Real ... the only national awards dedicated to recognizing excellence in the areas of healthcare ... presented in nine different categories during the GlobeSt Healthcare Conference today in Scottsdale, ...
(Date:12/2/2019)... ... December 02, 2019 , ... TrialScope, the global leader ... the North American branch of the healthcare business of Merck KGaA, Darmstadt, Germany, ... educate and inform patients, caregivers, the public, patient advocacy groups and healthcare professionals ...
Breaking Medicine News(10 mins):
(Date:12/6/2019)... ... December 06, 2019 , ... ... of treatments for psychiatric and neurodegenerative disorders, announced today that the U.S. Food ... NBTX-001 Inhaler, allowing the Company to initiate its Phase 2b trial for the ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... entrance into the Amazon Web Services (AWS) Public Sector Partner Program; a ... Public Sector Partner program recognizes and collaborates with partners that offer solutions ...
(Date:12/4/2019)... ... December 04, 2019 , ... Tenex ... minimally invasive technologies to treat chronic pain in soft and hard tissue, recently ... TX® technology. , Dr. Bernard Morrey, Chief Medical Officer of Tenex ...
Breaking Medicine Technology: